VaheyGMLindseyNPStaplesJEHillsSL. La crosse virus disease in the United States, 2003-2019. Am J Trop Med Hyg. 2021;105(3):807-812. doi:10.4269/ajtmh.21-0294.
3.
ThompsonWHKalfayanBAnslowRO. Isolation of California encephalitis group virus from a fatal human illness1. Am J Epidemiol. 1965;81:245-253. doi:10.1093/oxfordjournals.aje.a120512.
4.
BalfourHHEdelmanCKBauerHSiemRA. California arbovirus (La crosse) infections. III. epidemiology of California encephalitis in Minnesota. J Infect Dis. 1976;133(3):293-301. doi:10.1093/infdis/133.3.293.
5.
McJunkinJEde los ReyesECIrazuztaJE, et al.La Crosse encephalitis in children. N Engl J Med. 2001;344(11):801-807. doi:10.1056/NEJM200103153441103.
6.
BasuRNairVWinklerCWWoodsTAFraserIDCPetersonKE. Age influences susceptibility of brain capillary endothelial cells to La Crosse virus infection and cell death. J Neuroinflammation. 2021;18(1):125. doi:10.1186/s12974-021-02173-4.
7.
EvansABPetersonKE. Throw out the map: Neuropathogenesis of the globally expanding California serogroup of orthobunyaviruses. Viruses. 2019;11(9):794. doi:10.3390/v11090794.
8.
HennesseyMJPastulaDMMacheskyK, et al.Investigation of acute flaccid paralysis reported with La Crosse virus infection, Ohio, USA, 2008-2014. Emerg Infect Dis. 2017;23(12):2075-2077. doi:10.3201/eid2312.170944.
9.
OjhaDWinklerCWLeungJM, et al.Rottlerin inhibits La Crosse virus-induced encephalitis in mice and blocks release of replicating virus from the Golgi body in neurons. Nature Microbiol. 2021;6(11):1398-1409. doi:10.1038/s41564-021-00968-y.
10.
SandlerZJFirpoMROmobaOSVuMNMenacheryVDMounceBC. Novel ionophores active against La Crosse virus identified through rapid antiviral screening. Antimicrob Agents Chemother. 2020;64(6):e00086-20. doi:10.1128/AAC.00086-20.
11.
SchuhTSchultzJMoellingKPavlovicJ. DNA-based vaccine against La Crosse virus: protective immune response mediated by neutralizing antibodies and CD4 + T cells. Hum Gene Ther. 1999;10(10):1649-1658. doi:10.1089/10430349950017653.
12.
PavlovicJSchultzJHeftiHPSchuhTMöllingK. DNA vaccination against La Crosse virus. Intervirology. 2000;43(4-6):312-321. doi:10.1159/000053999.
13.
BennettRSGreskoAKNelsonJTMurphyBRWhiteheadSS. A recombinant chimeric La Crosse virus expressing the surface glycoproteins of jamestown canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys. J Virol. 2012;86(1):420-426. doi:10.1128/JVI.02327-10.
